Introducing Oliver Zill, VP of Computational Biology at ImmuneBridge We are thrilled to spotlight Oliver Zill, who leads ImmuneBridge’s Genomics and Data Platform initiatives. An industry veteran with over 20 years of experience in oncology, immunology, and genomics R&D, Oliver’s expertise is pivotal in propelling our capabilities to utilize high-dimensional data and computational algorithms for donor selection and cell therapy optimization. With previous roles at Genentech and Guardant Health, Oliver has led Computational Biology R&D groups and cross-functional product development teams for T-cell therapies, neoantigen vaccines, and circulating tumor DNA diagnostics. Most recently, he founded init.bio, a company that helps startups design and build computational platforms and teams for drug development. Oliver shares what drew him to ImmuneBridge: “I was captivated by ImmuneBridge’s mission to develop best-in-class allogeneic NK cell therapies—and that our approach flips the donor diversity ‘problem’ on its head. The data set we are generating provides a unique opportunity to employ modern techniques for high-dimensional data analysis and machine learning to make a major impact in immune cell therapies for cancer. Additionally, my graduate work involved leveraging inter-species variation to better understand gene regulation mechanisms, so ImmuneBridge’s strategy of leveraging genomic variation across individuals to identify the best candidates for cell therapies deeply resonated with me.“ Oliver's journey and vision are integral to our mission at ImmuneBridge, as we use computational approaches to characterize and harness humanity’s rich immune diversity to forge groundbreaking cancer therapies. #NKcelltherapy #Team #CompBio
Dr. Oliver Zill is the best!
It’s great to have you at the helm, Oliver!
Cute kids 😁
Congrats Oliver
Congrats! Oliver
Congrats Oliver Zill !
Director @ Gilead Sciences | Bioinformatics, Statistical Data Analysis
3moExciting times! Congratulations Oliver Zill. Looking forward to seeing your progress 😀.